HSPB1 and Hypoglycemia: HSPB1 (Fig. 3A), SMAD3 (Fig. 3B) and HSPA1A (Fig. 3C) decreased significantly (1300.0 ± 113.7 vs 1765.6 ± 146.7 RFU of HSPB1, hypoglycemia vs baseline, p < 0.05, 3650.4 ± 116.1 vs 4443.5 ± 264.5 RFU of SMAD3, hypoglycemia vs baseline, p < 0.01 and 4673.1 ± 316.5 vs 5685.5 ± 242.1 RFU of HSPA1A hypoglycemia vs baseline in control, p < 0.05), whilst MAPKAP5 increased significantly (737.2 ± 70.6 vs 561.6 ± 40.0 RFU of MAPKAP5, hypoglycemia vs baseline in control, p < 0.05) in controls from baseline to hypoglycemia (Fig. 3D).